Urology treats urinary tract diseases in all genders and male reproductive issues, covering the kidneys, bladder, prostate, urethra, from infections to complex cancers.
Send us all your questions or requests, and our expert team will assist you.
The journey to a robotic prostatectomy begins with a robust diagnostic evaluation designed to confirm the presence of cancer, assess its aggressiveness (grade), and determine its anatomical extent (stage). This pathway has evolved from simple random biopsies to a sophisticated, image-guided, and genomically informed process. The goal is to identify clinically significant disease that warrants radical surgical intervention while avoiding the over-treatment of indolent, low-risk cancers.
The initial screening relies on the Prostate-Specific Antigen (PSA) test and the Digital Rectal Examination (DRE). PSA is a glycoprotein enzyme produced by the epithelial cells of the prostate. Under normal conditions, it is secreted into the seminal fluid to liquefy semen. In the presence of cancer, the disruption of the standard glandular architecture allows PSA to leak into the bloodstream. While PSA kinetics (velocity and doubling time) provide valuable data, an elevated PSA alone is insufficient for diagnosis. The DRE allows the clinician to palpate the posterior prostate surface for nodules, induration, or asymmetry, providing a tactile assessment of the gland’s consistency.
The most significant advancement in prostate cancer diagnosis in the last decade is the integration of Multiparametric MRI (mpMRI). This imaging modality is performed before a biopsy in many protocols. It utilizes strong magnetic fields and radio waves to create detailed cross-sectional images of the prostate.
“Multiparametric” refers to the use of different MRI sequences to evaluate tissue properties:
Radiologists interpret these images using the PI-RADS (Prostate Imaging Reporting and Data System) scoring system, rating lesions from 1 (highly likely benign) to 5 (highly likely malignant). This roadmap allows for targeted sampling of suspicious areas.
Before proceeding to robotic prostatectomy, it is imperative to ensure the cancer is localized. Metastatic evaluation is reserved for patients with high-risk features (high PSA, high Gleason score, or palpable nodules).
A definitive diagnosis requires tissue. The standard of care has shifted towards MRI-Ultrasound Fusion Biopsy. This technique overlays the detailed MRI images (where the tumor is visible) onto real-time ultrasound images (used to guide the needle) during the procedure. This allows the urologist to accurately target the specific PI-RADS lesions identified on the MRI rather than unthinkingly sampling the prostate.
Biopsies can be performed via a transrectal approach (through the rectal wall) or a transperineal approach (through the skin between the scrotum and anus). The transperineal approach is gaining favor as it significantly reduces the risk of infection (sepsis) by avoiding the rectum and allows better access to anterior tumors. The tissue cores obtained are analyzed by a pathologist who assigns a Gleason Score (or Grade Group). This histological grading describes how abnormal the glandular cells look and predicts the potential for growth and spread. High-grade cancers (Gleason 7-10) are the primary targets for robotic prostatectomy.
In the era of precision medicine, cellular analysis extends beyond the microscope. Genomic classifiers (such as Decipher, Oncotype DX, or Prolaris) analyze RNA expression of specific genes in biopsy tissue. These tests evaluate the tumor’s biological behavior at the molecular level, predicting the risk of metastasis and adverse pathology.
For patients with intermediate-risk cancer, these genomic tests act as a tie-breaker. A high genomic risk score might push a patient toward surgery, while a low score might validate a decision for Active Surveillance (monitoring without surgery). This aligns with the regenerative philosophy of preserving the body’s integrity by avoiding surgery when the tumor’s biology does not demand it.
Once the oncological diagnosis is confirmed, the patient undergoes a physiological assessment to ensure fitness for robotic surgery and anesthesia. This includes cardiac clearance (EKG, stress tests), pulmonary function evaluation (critical due to the steep head-down position used during surgery), and assessment of blood coagulation status.
In some cases, a cystoscopy (camera in the urethra) may be performed if there is a concern about urethral strictures or large median lobes of the prostate protruding into the bladder, which could alter the surgical approach. The goal is to have a complete anatomical and physiological map of the patient before the first incision.
Send us all your questions or requests, and our expert team will assist you.
PI-RADS stands for Prostate Imaging Reporting and Data System. It is a scoring scale from 1 to 5 used by radiologists to report MRI findings. A score of 1 or 2 means clinically significant cancer is highly unlikely. A score of 3 is equivocal. A score of 4 or 5 indicates a high likelihood of substantial cancer, usually triggering a targeted biopsy.
A standard biopsy involves taking random samples from the prostate, which can miss a tumor located between the needles. A fusion biopsy uses MRI data to create a map, guiding the needle directly to the suspicious area. This increases diagnostic accuracy and reduces the risk of missing aggressive cancers or overdiagnosing insignificant ones.
The Gleason Score is the grading system used to determine the aggressiveness of prostate cancer cells under a microscope. It consists of two numbers (e.g., 3 + 4 = 7). The higher the score, the more abnormal the cells look and the more likely the cancer is to grow and spread. It is the most critical factor in deciding whether surgery is needed.
In many advanced medical centers, PSMA PET-CT is replacing traditional bone scans and CT scans for high-risk patients because it is much more sensitive. It can detect much smaller deposits of cancer cells. However, it is not used for every patient; it is typically reserved for those with high-risk features or suspected recurrence.
Active Surveillance is a management strategy for low-risk, slow-growing prostate cancer. Instead of immediate surgery or radiation, the patient is monitored closely with regular PSA tests, exams, and biopsies. Surgery is only performed if tests show the cancer is becoming more aggressive. This preserves quality of life and avoids side effects for cancers that may never cause harm.
BlogRobotic ProstatectomyNov 03, 2025Having prostate removal surgery is a big deal, both emotionally and physically. Medical News Today says hor...
BlogRobotic ProstatectomyNov 03, 2025Every year, over 200,000 men in the United States have prostate surgery. It’s a big deal, and knowing...
BlogRobotic ProstatectomyNov 03, 2025Understand the post prostatectomy recovery process - from hospital stays to resuming work, our experts prov...
BlogRobotic ProstatectomyDec 19, 2025Robotic prostatectomy is a new way to remove the prostate gland. It uses advanced robotic technology for pr...
BlogRobotic ProstatectomyDec 19, 2025Getting ready for robotic prostate surgery is key for a quick recovery. These tests include blood work and...
BlogRobotic ProstatectomyNov 03, 2025Men with prostate cancer or other prostate issues often face surgery as a treatment. Many men find the pros...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 174 28 17
